Clinical trial
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
NCT02999854 is registered in ClinicalTrials.gov with Kiadis Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
- Lead sponsor
- Kiadis Pharma
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 29, 2017
- Completion date
- December 17, 2021
- Enrollment
- 63 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome